Adding dulaglutide only slightly decreases major adverse CV events in patients with T2DM and CVD risk factors (REWIND)
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Barry, Henry, et al., editors. "Adding Dulaglutide Only Slightly Decreases Major Adverse CV Events in Patients With T2DM and CVD Risk Factors (REWIND)." EE+ POEM Archive, John Wiley & Sons, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314844/0/images/.
Adding dulaglutide only slightly decreases major adverse CV events in patients with T2DM and CVD risk factors (REWIND). In: Barry HH, Ebell MHM, Shaughnessy AFA, et al, eds. EE+ POEM Archive. John Wiley & Sons; 2019. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314844/0/images/. Accessed May 20, 2024.
Adding dulaglutide only slightly decreases major adverse CV events in patients with T2DM and CVD risk factors (REWIND). (2019). In Barry, H., Ebell, M. H., Shaughnessy, A. F., & Slawson, D. C. (Eds.), EE+ POEM Archive. John Wiley & Sons. https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314844/0/images/
Adding Dulaglutide Only Slightly Decreases Major Adverse CV Events in Patients With T2DM and CVD Risk Factors (REWIND) [Internet]. In: Barry HH, Ebell MHM, Shaughnessy AFA, Slawson DCD, editors. EE+ POEM Archive. John Wiley & Sons; 2019. [cited 2024 May 20]. Available from: https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314844/0/images/.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Adding dulaglutide only slightly decreases major adverse CV events in patients with T2DM and CVD risk factors (REWIND)
ID - 1314844
ED - Barry,Henry,
ED - Ebell,Mark H,
ED - Shaughnessy,Allen F,
ED - Slawson,David C,
BT - EE+ POEM Archive
UR - https://evidence.unboundmedicine.com/evidence/view/infoPOEMs/1314844/0/images/
PB - John Wiley & Sons
DB - Evidence Central
DP - Unbound Medicine
ER -